

# Christof von Kalle

## Scientific Vita

- 2005 – present Chair, Board of Directors, NCT; Director, Department of Translational Oncology, NCT and DKFZ, Heidelberg, Germany
- 2005 - 2008 Adjunct professor, Pediatrics, Cincinnati Children's Hospital Medical Center, Division of Experimental Hematology, Cincinnati, OH, USA
- 2004 - 2005 Tenured associate professor, Internal Medicine, Freiburg University, Germany
- 2002 - 2005 Associate professor, Pediatrics, program leader "Gene and Molecular Therapy", Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
- 2000 - 2005 Group leader, Section of Hematopoiesis and Gene Transfer, Institute for Molecular Medicine, Freiburg University, Germany
- 1996 - 2005 Senior clinical investigator, Gene Therapy Program, and senior medical staff fellow, Department of Internal Medicine, Freiburg University Medical School
- 1995 - 1996 Clinical investigator and senior resident, Department of Internal Medicine, University of Cologne Medical School, Germany
- 1992 - 1994 Associate in clinical research, Program of Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 1991 Medical PhD degree

## Awards

- 2014 Pioneer Series Award, Human Gene Therapy
- 2011 Eva Luise Köhler Award for Rare Diseases
- 2005 Langen Research Award, Paul-Ehrlich-Institute, Langen, Germany
- 2004 Elected, American Society of Clinical Investigation (ASCI)
- 2003 Young Investigator Award, American Society of Gene Therapy (ASGT)
- 1999 van Bekkum Award, European Group for Blood and Marrow Transplantation (EGBMT)

## Fields of Interest

Haematology, oncology; short and long term hematopoiesis, clinical research, molecular and gene therapy for cancer and inherited diseases, cancer stem cells, retrovirology.

## Most Important Publications (selection out of 150)

1. Biasco L, ..., Schmidt M, **Von Kalle C**, Roncarolo MG, Ciceri F, Vicard P, Wit E, Di Serio C, Naldini L, Aiuti A. In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases. *Cell Stem Cell*. 2016 Jul 7;19(1):107-19. doi: 10.1016/j.stem.2016.04.016. Epub 2016 May 26.
2. Gabriel, R, **von Kalle, C**, Schmidt, M. Mapping the precision of genome editing. *Nat Biotechnol* 2015; 33(2):150-152.

3. Ruggiero E,..., **von Kalle C**. High-resolution analysis of the human T-cell receptor repertoire. *Nat Commun* 2015; 6:8081.
4. Dietrich S,..., **von Kalle C**, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. *Blood* 2015; 126(8):1005-8.
5. Kaepfel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, **von Kalle C**, Petry H, Gaudet D, Schmidt M. A largely random AAV integration profile after LPLD gene therapy. *Nat Med* 2013; 19(7):889-91.
6. Aiuti A, *et al.* Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. *Science* 2013; 341(6148):1233151.
7. Ranzani M, *et al.* Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. *Nat Methods* 2013; 10(2):155-61.
8. Dietrich S, Glimm H, Andrulis M, **von Kalle C**, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. *N Engl J Med* 2012; 366(21):2038-40.
9. Dieter SM,..., **von Kalle C**, Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. *Cell Stem Cell* 2011, 9(4):357-65.
10. Gabriel R....**von Kalle C**. An unbiased genome-wide analysis of zinc-finger nuclease specificity. *Nat Biotech* 2011, 29(9):816-23.